Market Cap | 18.74M | P/E | - | EPS this Y | 65.80% | Ern Qtrly Grth | - |
Income | -38.77M | Forward P/E | -6.15 | EPS next Y | 22.00% | 50D Avg Chg | -16.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -19.00% |
Dividend | N/A | Price/Book | 0.28 | EPS next 5Y | - | 52W High Chg | -58.00% |
Recommedations | 2.00 | Quick Ratio | 14.73 | Shares Outstanding | 9.40M | 52W Low Chg | 24.00% |
Insider Own | 16.02% | ROA | -7.92% | Shares Float | 6.29M | Beta | 1.53 |
Inst Own | 12.13% | ROE | -48.05% | Shares Shorted/Prior | 1.41K/23.16K | Price | 2.52 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 26,259 | Target Price | 5.93 |
Oper. Margin | - | Earnings Date | Jun 21 | Volume | 4,311 | Change | -2.33% |
Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Kavuru Vimal | Director Director | Sep 25 | Buy | 1.848 | 676,371 | 1,249,934 | 1,188,076 | 09/27/23 |